References
- PailleFMartiniHNalmefene: a new approach to the treatment of alcohol dependenceSubst Abuse Rehabil20145879425187751
- BraillonAGrangerBWho can really benefit from nalmefene? Conclusions from independent evaluationsEncephaleIn press2015
- FranceCPGerakLRBehavioral effects of 6-methylene naltrexone (nalmefene) in rhesus monkeysJ Pharmacol Exp Ther199427039929997932212
- GarbuttJCKranzlerHRO’MalleySSVivitrex Study GroupEfficacy and tolerability of long-acting injectable naltrexonefor alcohol dependence: a randomized controlled trialJAMA2005293131617162515811981
- JonasDEAmickHRPharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysisJAMA2014311181889190024825644
- LhuintreJPDaoustMMooreNDAbility of calcium bis acetyl Homotaurine, a GABA agonist, to prevent prevention relapse in alcoholics WeanedLancet198518436101410162859465
- Van den BrinkWAubinHJBladströmATorupLGualAMannKEfficacy of as-needed nalmefene in alcohol-dependent patients with at least a high risk drinking level: results from a subgroup analysis of two randomized controlled 6-month studiesAlcohol Alcohol20134857057823873853
- GualAHeYTorupLvan den BrinkWMannKESENSE 2 Study Group. A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependenceEur Neuropsychopharmacol2013231432144223562264
- BraillonANalmefene in alcohol misuse:junk assessment by the European Medicines AgencyBMJ2014348g201724614566
- Van den BrinkWSørensenPTorupLMannKGualASENSE for the Study GroupLong-term efficacy, safety and tolerability of nalmefene as-needed in patients with alcohol dependence: A 1-year, randomized controlled studyJ Psychopharmacol20142873374424671340
- WurstFMKempterCSeidlSAltAEthyl glucuronide – a marker ofalcoholconsumption and a relapse marker with clinical and forensic implicationsAlcohol Alcohol199934171710075405
- PenderyMLMaltzmanIMWestLJControlled drinking by alcoholics? New Findings and a reassessment of a major affirmative studyScience198221745551691757089552
- MuckleWMuckleJWelchVTugwellPManaged alcohol as a harm reduction response for alcohol addiction in populations at high risk for substance abuseCochrane Database Syst Rev122012CD00674723235633
- SpenceDBad medicine: nalmefene in alcohol misuseBMJ2014348g153124531208
- Prescire. NalmefeneAlcohol dependence: no advancePrescrire Int20142315015015225121147
References
- Guideline on the development of medicinal products for the treatment of alcohol dependenceEuropean Medicines Agency2182010 EMA/CHMP/EWP/20097/2008. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/03/WC500074898.pdfAccessed May 18, 2015
- Alcoholism: Developing Drugs for Treatment Guidance for IndustryFood and Drug Administration22015 Available from: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm433618.pdfAccessed May 18, 2015
- MaistoSASobellLCCooperAMSobellMBComparison of two techniques to obtain retrospective reports of drinking behavior from alcohol abusersAddict Behav1982733387080882
- BaborTFSteinbergKAntonRDel BocaFTalk is cheap: measuring drinking outcomes in clinical trialsJ Stud Alcohol200061556310627097
- AubinHJReimerJNuttDJClinical relevance of as-needed treatment with nalmefene in alcohol-dependent patientsEur Addict Res20152116016825832297
- FillmoreKMKerrWCBostromAChanges in drinking status, serious illness and mortalityJ Stud Alcohol20036427828512713203
- GualALligoñaAColomJFive-year outcome in alcohol dependence. A naturalistic study of 850 patients in CataloniaAlcohol Alcohol19993418319210344779
- RehmJRoereckeMReduction of drinking in problem drinkers and all-cause mortalityAlcohol Alcohol20134850951323531718
- DawsonDAGoldsteinRBGrantBFRates and correlates of relapse among individuals in remission from DSM-IV alcohol dependence: a 3-year follow-upAlcohol Clin Exp Res2007312036204518034696
- MuckleWMuckleJWelchVTugwellPManaged alcohol as a harm reduction intervention for alcohol addiction in populations at high risk for substance abuseCochrane Database Syst Rev201212CD00674
- MaiselNCBlodgettJCWilbournePLHumphreysKFinneyJWMeta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful?Addiction201310827529323075288
- StevensonMPandorAStevensJWNalmefene for Reducing Alcohol Consumption in People with Alcohol Dependence: An Evidence Review Group Perspective of a NICE Single Technology AppraisalPharmacoeconomics Epub482015